Fairview CEO: Epic 'one of the biggest impediments to innovation' in healthcare

James Hereford, president CEO of Minneapolis-based Fairview Health Services had some harsh words for electronic health records giant Epic, calling for his fellow healthcare executives to band together to counter Epic’s clout in the industry.

At a forum hosted by the Minneapolis-St. Paul Business Journal, Hereford called Epic “one of the biggest impediments to innovation in health care” because of how the Wisconsin-based company “thinks about their (intellectual property) and the IP of others that develop on that platform.”

“There are literally billions of dollars in the Silicon Valley chasing innovation in health care. Yet Epic has architected an organization that has its belief that all good ideas are from Madison, Wisconsin. And on the off chance that one of us think of a good idea, it’s still owned by Madison, Wisconsin,” he said.

Pressure from executives, he said, may force Epic to change its approach.

“There is an opportunity for us to go to Epic and say, 'Look, you have to open up this platform,’” he said. “It’s for our benefit in terms of having an innovative platform where all these bright, amazing entrepreneurs can actually have access to what is essentially 80 percent of the U.S. population that is cared for within an Epic environment. I would love for us to get together to see how we march on Madison.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.